Follow
Jaap Verweij
Jaap Verweij
Erasmus University Medical Center and Cancer Drug Development Forum
Verified email at cddf.org
Title
Cited by
Cited by
Year
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ...
European journal of cancer 45 (2), 228-247, 2009
277352009
New guidelines to evaluate the response to treatment in solid tumors
P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, ...
Journal of the national cancer institute 92 (3), 205-216, 2000
188132000
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ...
The Lancet 368 (9544), 1329-1338, 2006
31632006
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom, J Verweij, K Nooter, A Sparreboom
European journal of cancer 37 (13), 1590-1598, 2001
21132001
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ...
The Lancet 364 (9440), 1127-1134, 2004
20922004
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
AT van Oosterom, I Judson, J Verweij, S Stroobants, ED di Paola, ...
The Lancet 358 (9291), 1421-1423, 2001
15872001
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
M Debiec-Rychter, R Sciot, A Le Cesne, M Schlemmer, P Hohenberger, ...
European journal of cancer 42 (8), 1093-1103, 2006
10622006
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...
The lancet oncology 15 (4), 415-423, 2014
9872014
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
RHJ Mathijssen, RJ van Alphen, J Verweij, WJ Loos, K Nooter, G Stoter, ...
Clinical cancer research 7 (8), 2182-2194, 2001
9232001
Pharmacological effects of formulation vehicles: implications for cancer chemotherapy
AJ Ten Tije, J Verweij, WJ Loos, A Sparreboom
Clinical pharmacokinetics 42, 665-685, 2003
8012003
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
JC Bendell, J Rodon, HA Burris, M De Jonge, J Verweij, D Birle, ...
J Clin Oncol 30 (3), 282-290, 2012
7722012
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for …
S Sleijfer, I Ray-Coquard, Z Papai, A Le Cesne, M Scurr, P Schöffski, ...
Journal of clinical oncology 27 (19), 3126-3132, 2009
7672009
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ...
Cancer research 69 (13), 5383-5391, 2009
7662009
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
RD Issels, LH Lindner, J Verweij, P Wust, P Reichardt, BC Schem, ...
The lancet oncology 11 (6), 561-570, 2010
7632010
Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia
PJ Valk, RG Verhaak, MA Beijen, CA Erpelinck
N Engl J Med 350 (16), 1617-28, 2004
649*2004
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a …
M Van Glabbeke, AT Van Oosterom, JW Oosterhuis, H Mouridsen, ...
Journal of Clinical Oncology 17 (1), 150-157, 1999
6341999
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for …
A Santoro, T Tursz, H Mouridsen, J Verweij, W Steward, R Somers, ...
Journal of Clinical Oncology 13 (7), 1537-1545, 1995
6291995
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II …
M Debiec-Rychter, H Dumez, I Judson, B Wasag, J Verweij, M Brown, ...
European journal of cancer 40 (5), 689-695, 2004
5832004
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European …
A Ardizzoni, H Hansen, P Dombernowsky, T Gamucci, S Kaplan, ...
Journal of clinical oncology 15 (5), 2090-2096, 1997
5801997
Effects of St. John's wort on irinotecan metabolism
RHJ Mathijssen, J Verweij, P De Bruijn, WJ Loos, A Sparreboom
Journal of the National Cancer Institute 94 (16), 1247-1249, 2002
5792002
The system can't perform the operation now. Try again later.
Articles 1–20